zepbound lilly - Search News

News

Eli Lilly Vows to Make Weight-Loss Pill in U.S.

Eli Lilly says GLP-1 pill for diabetes and weight loss effective in study, plans to seek FDA approval

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.

Insider on MSN · 1d

Weight loss in a pill? Eli Lilly just took a big step closer to making it happen.

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial results.

Axios on MSN · 1d

GLP-1 pill: Eli Lilly says its oral orforglipron showing "promising results"

A new oral GLP-1 drug candidate could transform the diabetes and weight loss drug boom. Why it matters: Eli Lilly said on Thursday that its experimental pill — called orforglipron — is showing promising results and could serve as an alternative to blockbuster injectable medications like Ozempic and Mounjaro.

Lilly’s Zepbound Keeps Weight Off for Three Years, Study Finds

Patients regularly taking Eli Lilly & Co.’s obesity shot Zepbound tend to keep the weight off for at least three years, with ...

1don MSN

Where Will Eli Lilly Be in 5 Years?

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

24/7 Wall St.17h

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (April 2025)

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Nikkei Asia1d

Eli Lilly releases obesity drug in Japan, targeting 'hidden' fat

U.S. drugmaker Eli Lilly has released its Zepbound obesity medication in Japan, targeting the millions said to suffer from the "hidden" scourge of buildups of visceral fat. "We believe there are 16 to ...

4don MSN

Wegovy, Zepbound makers’ stocks rally as a weight-loss-drug competitor drops out

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results